Cecilia Ching Sze Yeung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cecilia Ching Sze Yeung has a total of 749 co-authors. Here are the top co-authors by number of shared publications:
- Raphael Gottardo
Biomedical Data Science Center, Lausanne University Hospital, Lausanne, Switzerland
71 shared publications - Elizabeth Donato
Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle WA
54 shared publications - William M. Grady
Fred Hutchinson Cancer Center, Seattle, Washington
54 shared publications - Armando E. Rodriguez Martinez
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington
50 shared publications - Greg Finak
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
50 shared publications - Jeffery Williams
Shared Resources, Fred Hutchinson Cancer Center, Seattle, Washington
50 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Society of Hematology in Blood
CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia
No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729
- 5 November 2026
- Published by American Society of Hematology in Blood
Open AccessCD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia
No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729
- Open Access
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Triple Therapy for CAR T-Related Guillain-Barré Syndrome: A Case Report
From the 2026 National Summit on Hematologic Cancers
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessTriple Therapy for CAR T-Related Guillain-Barré Syndrome: A Case Report
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S1 – Demographics and Baseline Characteristics for All Enrolled Subjects.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S1 – Demographics and Baseline Characteristics for All Enrolled Subjects.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S2. Representativeness of Study Participants.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S2. Representativeness of Study Participants.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S4 – Toxicities Possibly, Probably or Definitely Related to First Infusion of CAR T Cells.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S4 – Toxicities Possibly, Probably or Definitely Related to First Infusion of CAR T Cells.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S3 – Bridging Therapy Received.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Table S3 – Bridging Therapy Received.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S1. A)Gating strategy of peripheral blood CAR T cell detection by flow cytometry. B)Gating strategy for paired 2GS/3GS products evaluating differentiation state and activation/exhaustion state by flow cytometry.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S1. A)Gating strategy of peripheral blood CAR T cell detection by flow cytometry. B)Gating strategy for paired 2GS/3GS products evaluating differentiation state and activation/exhaustion state by flow cytometry.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S2. Differential expression by flow cytometry of differentiation (A + B), activation/exhaustion markers (C + D) of paired 2GS and 3GS products for the 6 patients who had both products generated, separated by CD4 (A + C) and CD8 (B + D) experiments, showing no statistical differences between paired 2GS and 3GS products.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S2. Differential expression by flow cytometry of differentiation (A + B), activation/exhaustion markers (C + D) of paired 2GS and 3GS products for the 6 patients who had both products generated, separated by CD4 (A + C) and CD8 (B + D) experiments, showing no statistical differences between paired 2GS and 3GS products.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S3. Kidney biopsy of S16 demonstrating A) no inflammatory infiltrate on H&E sections, B)intact CD171+ renal tubules and C) no CD3+ infiltrate.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S3. Kidney biopsy of S16 demonstrating A) no inflammatory infiltrate on H&E sections, B)intact CD171+ renal tubules and C) no CD3+ infiltrate.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S4. Pre- and post-CAR T peripheral blood cytokine profiling comparing cytokines for patients on Arm A and Arm B, showing no statistical differences between groups.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma
Supplementary Figure S4. Pre- and post-CAR T peripheral blood cytokine profiling comparing cytokines for patients on Arm A and Arm B, showing no statistical differences between groups.